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ABSTRACT
Motivation: How do we integratively analyze large-scale multi-
platform genomic data that are high dimensional and sparse? Fur-
thermore, how can we incorporate prior knowledge, such as the
association between genes, in the analysis systematically?
Method: To solve this problem, we propose a Scalable Network
ConstrainedTucker decompositionmethodwe call SNeCT. SNeCT
adopts parallel stochastic gradient descent approach on the pro-
posed parallelizable network constrained optimization function. SNeCT
decomposition is applied to tensor constructed from large scale
multi-platform multi-cohort cancer data, PanCan12, constrained
on a network built from PathwayCommons database.
Results: The decomposed factor matrices are applied to stratify
cancers, to search for top-k similar patients, and to illustrate how
the matrices can be used for personalized interpretation. In the
stratification test, combined twelve-cohort data is clustered to form
thirteen subclasses. The thirteen subclasses have a high correla-
tion to tissue of origin in addition to other interesting observations,
such as clear separation of OV cancers to two groups, and high clin-
ical correlation within subclusters formed in cohorts BRCA and
UCEC. In the top-k search, a new patient’s genomic profile is gen-
erated and searched against existing patients based on the factor
matrices. The similarity of the top-k patient to the query is high for
23 clinical features, including estrogen/progesterone receptor sta-
tuses of BRCA patients with average precision value ranges from
0.72 to 0.86 and from 0.68 to 0.86, respectively. We also provide an
illustration of how the factormatrices can be used for interpretable
personalized analysis of each patient.
Availability: The code and data available at our repository1.
Supplementary information: Supplementary data are available
at Bioinformatics online.
1 INTRODUCTION
Integrative analysis of multiple perspectives of a patient helps in
both stratification and clinical predictions. Stratification helps the
researchers in understanding and exploring the genomic charac-
teristics in relation to their current phenotypes and thus to recog-
nize opportunities for clinical improvement on stratified groups of
patients. In the perspective of personalized medicine, clinical di-
agnostics and predictions of individual patient is needed and can
be done by searching the integrated profile of a patient to existing
records. Analysis of one or few data types may not be sufficient
for stratifications or accurate predictions of disease as they only
provide partial information about the patient’s biological status.
Related works in integrative genomic analysis: Need for in-
tegrative data analysis methods is being recognized, however, due
1 https://github.com/skywalker5/SNeCT
to increased sized of data and a limited number of uniform data
analysis framework, integrative analysis of multiple data types is
still a challenging task. Existing methods are often limited in inter-
pretability and scalability and often runs in selected subset of data
and features. Other methods run only on small number of genes
such as work by [14] that shows the effect of DNAmethylation and
CNV in gene expression of several known oncogenes for glioblas-
toma and ovarian cancer; PARADIGM method by [29] that adopts
graph inference approach on augmented pathway structure con-
taining nodes for CNV, gene expression, protein expression and
active protein information; and a work by [24] that proposes an
integrative statistical framework based on a sparse regression of
gene expression values based on CNV, miRNA, and methylation.
Manymethods run only on small data sets, such as multiple-kernel
based method by [26, 27] that combines kernels generated from
individual platform data in a weighted linear fashion for stratifi-
cation and predictions of ovarian cancer; a method by [15] that
applies multivariate Cox Lasso model and median time-to-event
prediction algorithm on dataset integrated from the CNV, methy-
lation, miRNA, and gene expression data; and iCluster method by
[17] that transforms multi-platform data to latent space and clus-
ters using latent variable. Also, many methods do not truly inte-
grate the data in the analysis such as work by [30] that evaluated
the predictive power of patient survival and clinical outcome using
clinical data in combination with one of CNV, methylation, mRNA,
miRNA or protein expression data, and work by [5] that stratifies
the PANCAN12 dataset using multi-platform data where cluster-
ing results of each data type are used to construct the final cluster.
Multi-platform multi-cancer data analysis: The data scalabil-
ity challenge in the integrative analysis is even more evident in
multi-platform data analysis across multiple cancer types. Analy-
sis across multiple cancer types enables us to get a glimpse of the
extent to which genomic signatures are shared across the different
cancers. The biological understanding of similarity and dissimilar-
ity among the different cancer types can enable efficient manage-
ment of diseases as well as treatment transfers between different
cancer types of similar genomic signatures. The work of [5] is one
of the first attempts to utilize multi-platform data of multiple can-
cers, i.e. the PanCan12 dataset. The PanCan12 dataset is created
by the Pan-Cancer initiative that compares 12 tumor types pro-
filed by The Cancer Genome Atlas (TCGA) Research Network and
includes data from six different platforms [3]. In their work, inte-
grated subtype classification for all of the tumor samples was per-
formed byfirst clustering on individual data platforms, and then us-
ing the results of single-platform clusters as input to a second-level
cluster analysis to form a cluster-of-cluster assignment (COCA).
Fully integrative data analysis method would consider and opti-
mize the multi-platform data altogether. In this perspective, the
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Figure 1: Overview of the tensor decomposition of SNeCT and validation processes.
COCA method can be considered as an ensemble method where
the input data are varied, rather than an integrative method. Also,
it is difficult to utilize the COCA approach for finding similar pa-
tients as needed in the clinical predictions given a new patient’s
data without redoing the analysis over again. Thus, there is a need
for multi-platform data analysis method that can scalably stratify
multiple cancer types for knowledge discovery and predict clinical
outcomes for enabling personalized medicine.
Relatedworks in tensor analysis: Tensors, i.e., multi-dimensional
arrays, are a natural representation ofmulti-platformgenomic data
[22]. The core of tensor analysis is tensor decomposition, which
can be considered as higher-order singular value decomposition
(HOSVD). Tensor analysis has been widely applied with success
on network traffic [16], knowledge bases [1, 19], hyperlinks and an-
chor texts in the Web graphs [10], sensor streams [25], and DBLP
conference-author-keyword relations [12], to name a few. The ma-
jor challenge of tensor analysis is data scalability as there is an in-
termediate data explosion problem in the decomposition process
even when the input tensor fits into the memory. To address this
problemwe have previously proposed a Hadoop based parallel ten-
sor decomposition method [6, 7] and a multi-core based method
[23].
Contributions: In this paper, we propose a tensor-based method
that enables stratification and clinical prediction of patients utiliz-
ing multi-platform data analysis across multiple cancer types. We
have shown in our previous works [8, 9] that somatic mutation
profiles generated from orthogonal matrix decomposition enable
accurate stratification and clinical predictions of each cancer type.
We extend this approach to multi-platformmulti-cancer data anal-
ysis by proposing a scalable network constrained Tucker decom-
position (SNeCT) method (Figure 1), and show that SNeCT can
efficiently stratify cancer subtypes and predict clinical outcomes.
The contributions of this paper are listed in the following.
• A novel scalable network constrained Tucker decomposition
(SNeCT) algorithm.
• Stratification onmulti-platformmulti-cohort data showing sim-
ilarity and difference between cancer cohorts.
• Individualized clinical prediction utilizing multi-platform ge-
nomic profiles.
• A demonstration of personalized interpretation utilizing factor
matrices.
2 MATERIALS AND METHODS
2.1 Data processing
2.1.1 Tensor constructionwith the PanCan12. Initially, Pan-Cancer-
12 data freeze version 4.7 was downloaded from the Sage Bionet-
works repository, Synapse [20]. The PanCan12 containsmulti-platform
data with mapped clinical information of patients group into co-
horts of twelve cancer type: bladder urothelial carcinoma (BLCA),
breast adenocarcinoma (BRCA), colon and rectal carcinoma (COAD,
READ), glioblastoma multiforme (GBM), head and neck squamous
cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC),
acute myeloid leukaemia (LAML), lung adenocarcinoma (LUAD),
lung squamous cell carcinoma (LUSC), ovarian serous carcinoma
(OV), and uterine corpus endometrial carcinoma (UCEC). Table 1
lists the Synapse IDs of the downloaded data for each platform
used. After download, probes of each platform are mapped to cor-
responding gene symbols. Then, subjects and genes that have less
than two evidences are removed from the dataset. The resulting
data for each platform are min-max normalized and is further nor-
malized such that the Frobenius norm, i.e.,‖A‖ ≡
√∑
i
∑
j |ai j |
2,
becomes one. A cell of resulting 3-mode tensor,X, contains a float-
ing point value indexed on <patient , дene ,plat f orm> as shown in
Figure 1. The size of the first mode spanning over subject or the
Table 1: TCGA PAN Cancer (PanCan12) freeze 4.7 and
Synapse repository.
Platform Input Data # of Genes # of Samples
P1. miRNA syn2491366 14,345 4198
P2. Methylation syn2486658 1,383 4919
P3. Somatic CNV syn1710678 876 3260
P4. mRNA syn1715755 14,178 3599
P5. Somatic SNV syn1729383 14,351 4933
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patient index is 4,555; the size of the second mode spanning over
the genes is 14,351; and the size of the third mode spans over five
different platforms.
2.1.2 Network constraint formation with pathway data. Links
between genes in gene-gene network is used for constraining the
factor matrices towards existing knowledge of gene associations.
The initial bio-network of human gene associations is retrieved
from version 8 of PathwayCommons [2]. The initial bio-network
is then used to construct adjacency matrix of gene network for the
list of gene considered in the tensor construction. The adjacency
matrix, Y, contains 665,429 number of association information of
14,351 genes.
2.2 Tensor basics
We describe the basic notations and operations on a tensor and
its decompositions. Table 2 shows the definitions of symbols used
in this paper. A tensor is a generalization of a multi-dimensional
array denoted by a boldface Euler script, e.g.X. An N -mode tensor
is denoted as X ∈ RI1×I2×···×IN , and (i1i2 · · · iN )-th elements of X
is denoted as xi1i2 · · ·iN . A matrix is denoted by an uppercase bold
letter, e.g.A. The i-th row vector ofA is denoted by ai in lowercase
bold letter, and the (ij)-th entry of A is denoted by ai j . All tensor
and matrix indices are positive integers greater than or equal to
1. The mode-n matrix product of a tensor X ∈ RI1×I2×···×IN with
a matrix A ∈ RIn×K is denoted by X ×n A and has the size of
I1 × · · · In−1 × K × In+1 · · · × IN . The element-wise definition is as
follows:
(X ×n A)i1 ...in−1jin+1 ...iN =
In∑
in=1
xi1i2...iN ajin . (1)
See [11] for detailed explanations about tensor operations. We fo-
cus on 3-mode tensor X ∈ RI1×I2×I3 for the following sections
since our dataset includes a 3-mode tensor (Section 2.1.1).
After construction of tensors, they can be decomposed in several
ways.We focus onhigher order singular value decomposition (HOSVD).
HOSVD, also known as Tucker decomposition, is the generaliza-
tion of singular value decomposition (SVD), which works on ma-
trices. HOSVD decomposes a tensor into a core tensor and orthog-
onal factor matrices corresponding to modes. Specifically, given a
3-mode data tensor X, HOSVD decomposesX as follows:
X ≈ X˜ = G ×1 U
(1) ×2 U
(2) ×3 U
(3), (2)
where G ∈ RJ1×J2×J3 is a core tensor, and U(n) ∈ RIn×Jn denotes
the factor matrices for the n-th dimensions, respectively. HOSVD
finds the factors by minimizing the following objective function:
f =
1
2
‖X − X˜‖2 +
λ
2
R(G,U(1),U(2),U(3)),
=
1
2
∑
(i jk)∈ΩX
(xi jk − G ×1 u
(1)
i ×2 u
(2)
j ×3 u
(3)
k
)2
+
λ
2
R(G,U(1),U(2),U(3)),
(3)
where R(G,U(1),U(2),U(3)) is the L2 regularization term. Perfor-
mance comparison of existing graph constrained HOSVD method
is provided in the Supplementary.
Table 2: Table of symbols.
Symbol Definition
X a tensor (boldface Euler script)
xi jk (ijk)-th entry of X
A a matrix (uppercase, bold letter)
ai the i-th row vector of A (lowercase, bold letter)
ai j (ij)-th entry of A
×n n-mode matrix product
‖ • ‖ Frobenius norm
∗ Hadamard product
◦ Outer product
⊘ Element-wise division
ΩX index set ofX
Ω
n,i
X
subset of ΩX having i as the n-th index
In length of n-th dimension of input tensor X
Jn length of n-th dimension of core tensor G
2.3 SNeCT decomposition
2.3.1 HOSVD optimization with network constraint. Consider
that a graph G represents a network between entities of a dimen-
sion. For our data tensor with dimensions of (patient, gene, plat-
form), G is the network of genes as explained in Section 2.1.2. G
informs the similarities between genes, e.g., gene i and gene j are
similar if yi j = 1. To include the similarity constraint to HOSVD,
the network graphG acts as a regularization as studied in previous
works of [13, 18]. Specifically, we add the network regularization
term λд fд to the objective function of Equation (3) where matrix
Y is the adjacency matrix of G constraining the second dimension,
and λд is a constant.
fд =
1
2
J2∑
l=1
[ ∑
(k1k2)∈ΩY
yk1k2 (u
(2)
k1l
− u
(2)
k2l
)2
]
=
1
2
∑
(k1k2)∈ΩY
yk1k2 ‖u
(2)
k1
− u
(2)
k2
‖2
(4)
where ΩY is the index set of Y. Minimizing fд guides the algorithm
such that the factors of associated genes become similar, i.e., u
(2)
j1
and u(2)j2 have similar values when there is an edge between gene
j1 and gene j2 in the graph G.
2.3.2 Parallelizable update rules. We present a multi-core algo-
rithm to minimize the objective function fopt = f + λд fд and
factorize the given tensorX into HOSVD form. SNeCT adopts par-
allel stochastic gradient descent (SGD) optimization technique, and
thus is highly memory-efficient and scalable to large datasets and
multiple cores. We rewrite f so that it forms an SGD-amenable
form.
f =
1
2
∑
(i1i2i3)∈ΩX
[ (
xi1i2i3 − x˜i1i2i3
)2
+
λ
|ΩX |
‖G‖2+λ
3∑
n=1
‖u
(n)
in
‖2
|Ω
n,in
X
|
]
Note that fд already has the SGD-amenable form and ΩX excludes
the cells with missing data. Now, gradients of fopt with respect to
factors for a given data point xα=(i1i2i3) or yβ=(k1k2) are calculated
as follows:
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Algorithm 1 SNeCT
Input: Input data: tensor X ∈ RI1×I2×···×IN , network matrix Y ∈ RIc×K , number of parallel cores P , and network-constrained mode c
Hyperparameters: core size (J1, J2, · · · , JN ), learning rate η, and regularization factors λ and λд
Output: Core tensor G ∈ RJ1×J2×···×JN , and factor matrices U(1), U(2), · · · , U(N )
1: Initialize G, U(n) ∈ RIn×Jn for n = 1, 2, · · · , N randomly
2: repeat
3: for ∀xi1i2 ···iN ∈ X, ∀yk1k2 ∈ Y in random order do in parallel
4: if xi1i2 ···iN ∈ X is picked then
5: Cache intermediate data tensor:D ← G ∗ (u(1)i1 ◦ u
(2)
i2
◦ · · · ◦ u
(N )
iN
)
6: x˜i1i2 ···iN ← sum of all elements ofD
7: Update corresponding factor rows: u(n)in ← u
(n)
in
− η
(
(x˜i1i2 ···iN − xi1i2 ···iN ) · Collapse(D, n) +
λ
|Ω
n, in
X
|
u
(n)
in
)
, (for n = 1, 2, · · · , N )
8: Update core tensor: G ← G − ηP
(
(x˜i1i2 ···iN − xi1i2 ···iN ) ·D ⊘ G +
λ
|ΩX |
G
)
, (executed by only one core)
9: end if
10: if yk1k2 ∈ Y is picked then
11: Update network-constrained factors: u(c)
k1
← u
(c)
k1
− ηλдyk1k2 (u
(c)
k1
− u
(c)
k2
), u(c)
k2
← u
(c)
k2
− ηλдyk1k2 (u
(c)
k2
− u
(c)
k1
)
12: end if
13: end for
14: until convergence conditions are satisfied
15: Q(n), R(n) ← QR decomposition of U(n), U(n) ← Q(n) , G ← G ×n R(n), (for n = 1, 2, · · · , N )
16: return G, U(1), U(2), · · · , U(N )
∂ fopt
∂u
(1)
i1

α
= −
(
xα − x˜α
) [
G ×2 u
(2)
(i2)
×3 u
(3)
(i3)
]
+
λ
|Ω
1,i1
X
|
u
(1)
i1
∂ fopt
∂G

α
= −
(
xα − x˜α
)
×1 u
(1)T
i1
×2 u
(2)T
i2
×3 u
(3)T
i3
+
λ
|ΩX |
G
∂ fopt
∂u
(2)
k1

β
= λдyβ (u
(2)
k1
− u
(2)
k2
)
(5)
∂fopt
∂u
(2)
i2

α
,
∂fopt
∂u
(3)
i3

α
, and
∂fopt
∂u
(2)
k2

β
are calculated symmetrically as the
above equations. The above equations are naturally generalized to
mode-N tensors.
2.3.3 SNeCT learningmodel. SNeCT optimizes the objective func-
tion fopt by parallel SGD update. Algorithm 1 shows detailed pro-
cedures of decomposition of a general N -mode tensor X and net-
work constraint Y which represents the similarity of c-th mode
entities.
In the beginning, SNeCT initializes U(1), U(2), · · · , U(N ), and G ran-
domly (line 1 of Algorithm 1). The outer loop (lines 2-14) repeats
until the factors converge. In the inner loop (lines 3-13), SNeCT
conducts parallel updates of factor rows corresponding to each
data point xi1i2i3 or yj1 j2 in random order. When calculating gradi-
ents with respect to factor rows and core tensor, it takes excessive
time to calculate x˜alpha = G×1u
(1)
i1
×2 · · ·×nu
(N )
iN
and tensor-matrix
products for
∂fopt
∂u
(n)
in
every time when they are needed. SNeCT re-
duces the time cost efficiently by caching intermediate data tensor
D (line 5). See section 3.5 of [4] for detailed approach of utilizing in-
termediate data to reduce time cost. Collapse(D,n) operator (line
7) outputs a vector with length of in which contains the sum of k-
th slice of D over n-th mode as its k-th element. In line 8, element-
wise division operator ⊘ is used to efficiently calculate core tensor
gradient.
There are possible conflicts between the parallel updates since a
factor row or core tensor might be accessed by multiple update at-
tempts. However, we apply lock-free parallel update scheme [4, 21]
and remove frequent conflicts by updating core tensor using only
one core (line 6); thus SNeCT guarantees near-linear convergence
to a local optimum.
3 RESULTS
3.1 Stratification
3.1.1 Cluster assignment. We perform cluster analysis with k-
means clustering algorithm on patient profiles using Euclidean dis-
tance. (Euclidean, cosine and Mahalanobis distance measures have
been tested with no significant differences in the results.) To gen-
erate patient profiles, SNeCT decompose the data tensor as shown
in Fig. 1 with core size [J1, J2, J3] = [78, 48, 5], where the best core
size was searched with a small validation tensor and graph con-
straint is set to λ = 1.0. After decomposition, the rows of patient
factor matrix U (1) is used as patient profiles. To find the cluster
size we compute the gap statistics introduced by [28]. The gap sta-
tistics of the cluster stabilizes after cluster size of 10 as shown in
Supplementary Fig. 3For convenience of comparison, we stratified
patient profiles into 13 clusters as suggested in [5]. Table 3 shows
the number of assigned patients of twelve cancer types for each
cluster.
3.1.2 Survival analysis. We performed survival analysis for the
thirteen clusters acquired from Section 3.1.1, using the Cox propor-
tional hazards regression model in the R survival package (Fig 2).
We use right-censored survival data for patients: days to death for
4
Table 3: 12 pathological disease types assigned to clusters of
profiles factorized from tensor factorizationwith graph con-
straint of λ = 1.0.
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 Total
BLCA 16 32 2 19 0 22 3 0 0 0 32 0 0 126
BRCA 17 3 600 172 1 70 0 0 0 0 26 0 0 889
COAD 4 0 2 2 0 91 317 0 0 0 1 2 0 419
GBM 4 1 1 2 3 7 0 0 248 0 1 0 0 267
HNSC 0 242 1 6 0 1 0 0 0 0 60 0 0 310
KIRC 14 1 1 0 471 4 0 0 1 0 6 0 0 498
LAML 0 0 0 0 0 9 0 0 0 188 0 0 0 197
LUAD 302 2 2 7 1 12 0 0 0 0 29 0 0 357
LUSC 26 32 0 29 0 7 0 0 0 0 246 0 0 340
OV 0 0 1 3 0 1 1 348 0 0 0 0 131 485
READ 1 1 0 5 0 9 145 0 0 0 1 1 0 163
UCEC 3 1 3 117 1 348 1 0 0 0 10 13 2 499
Total 387 315 613 362 477 581 467 348 249 188 412 17 134 4550
dead patients, and days to last contact for alive patients as right-
censored data. To see how the network constraint affects decom-
position result, we impose three different levels of network regu-
larization: λд value of 0 (not constrained), 0.1, and 1. The log-rank
statistics value for λд = 0 is 409, for λд = 0.1 is 1151, and for λд = 1
is 1185. The Figure 2 and the log-rank statistics values show that
having graph constraint is better, however, little difference is ob-
served for the two weight values.
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Figure 2: Predicted survival curves for clustered patients. x-
axis is survival time (day) and y-axis is survival rate.
3.1.3 Unique cohort clusters. Cluster result of the patient fac-
tor matrix, U(1), correlates with tissue of origin which is similar
to observation made by [5]. Six clusters, C1-LUAD-enriched, C3-
BRCA/Luminal, C5-KIRC, C8-OV-1, C9-GBM, C10-LAML, and C13-
OV-2 each dominantly contains cancer samples from a single tis-
sue of origin. Patients in C1-LUAD-enriched cluster includes 302
out of 357 LUAD patients with relatively good prognosis, that is,
neoplasm cancer status is tumor free for 186 out of all 217 tumor
free cases with precision of 0.73 (recall of 0.85). Patients in C3-
BRCA/Luminal cluster groups 600 BRCA cases with 13 other can-
cer types. The BRCA patients in C3 have positive estrogen and
progesterone receptor status with precision of 0.95 and 0.85, re-
spectively, and HER2 status is mixed tending to have more nega-
tive status with precision of 0.73. Furthermore, C3 contains 8 out
of 9 metastatic cases and contains 34 out of 43 cases with known
other malignancy histological type. It tells us that C3 groups pa-
tients with BRCA Luminal A and Luminal B molecular subtypes
of breast cancer. Four other clusters that form somewhat mutually
exclusive collectively exhaustive groups are cluster C5-KIRC that
contains 471 patients classified as KIRC and 6 patients classified
to other cancer types, cluster C9-GBM that contains 248 cases of
GBM patients with only one of KIRC patient, cluster C10-LAML
that contains 188 cases of LAML with no other cancer patients in-
cluded, and cluster C12-UCEC-small, a small cluster, that contains
13 UCEC with 4 other cases with very high survival ratio as shown
in Fig. 3(c).
Interestingly, two clusters are formed for OV cases: C13-OV-2 that
contains 131 cases of OV patient with only three other cancer types
and cluster C8-OV-1 that contains 348 cases of OV patients with no
other cancer type. There is no clear distinction between the clinical
features of the two clusters. However, a clear distinction can be
found comparing factor values of genomic contents for C13, C8,
and other clusters, as shown in Supplementary Fig. 4(a).Separation
can also be found in the survival analysis of C8 and C13 (Fig. 3(a)).
Another interesting cluster is C7-COAD/READ that combines two
colorectal tumor samples from cohorts COAD and READ with C7
READcontaining almost all READ cases (145 out of 163). C7 COAD
group contains 22 (precision 1 and recall of 0.88) normal braf gene
analysis results while C6 COAD contains all three cases of abnor-
mal braf gene analysis result. C7 COAD tends to have better sur-
vival ratio compared to C6 COAD cases as shown in Supplemen-
tary Fig. 5.
3.1.4 Squamous-like cluster. Patients in the C2-HNSC-enriched-
squamous-like cluster contains squamous-like BLCA (32), HNSC
(242), and LUSC (32) of mostly male (228/315) patients. 242 out
of 310 HNSC patients are group to C2 where 60 other HNSC pa-
tients are grouped in another squamous-like cluster C11 that con-
tains 246 out of 340 LUSC patients. Also, within C2 cluster, BLCA
group contains 26 patients diagnosed as non-papillary with a preci-
sion of 0.79 and mixed neoplasm cancer status (14 tumor free and
13 with tumor) and contains 9 cases of having other malignancy
histological type. LUSC and HNSC patients in group C2 do not
show clear characteristics in terms of clinical features other then
being skewed towards male gender. Cluster C11-LUSC-enriched-
squamous-like contains a mixed group of 32 BLCA, 26 BRCA, 60
HNSC, 29 LUAD, and 246 LUSC cancer patients. The LUSC cases
within C11 contains 128 patients and tends to be skewed towards
patients with higher level of smoking history (level 4 - 130/174,
level 3 - 43/67, level 2 61/79 and level 1 - 6/13) but with slightly bet-
ter prognosis (tumor free 142 out of 198 and with tumor 38 out of
56); HNSC patients in C11 have mixed neoplasm cancer statuses
(tumor free 36 and with tumor 18) and are mostly of intermedi-
ate histological grade (41 of grade g2 and 15 of grade g3). BRCA
patients in the group tend to have negative progesterone receptor
status (20 negatives; 4 positives), negative estrogen receptor status
(16 negatives; 8 positives), negative HER2 status (14 negatives; 3
positives; 3 equivocals), contains many (24) infiltrating ductal car-
cinoma cases, and tend to have the worst prognostics (Fig. 3(a)).
3.1.5 BRCA/UCEC clusters. TwoBRCA/UCEC-enriched clusters
are formed as C4 and C6. C4-BRCA/UCEC-enriched cluster con-
tains 172 BRCA and 117 UCEC cases mixed with 29 LUSC and 19
BLCA cases. C6-BRCA/UCEC-enriched cluster contains 70 BRCA
and 348 UCEC cases mixed with 90 COAD and 22 BLCA cases. Pa-
tients in C4 BRCA has mostly negative estrogen receptor status
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Figure 3: Survival analysis of clusters for cohorts OV (A),
BRCA (B), and UCEC (C).
(127 negative cases with precision 0.77; 38 positives), mostly neg-
ative progesterone receptor status (131 negatives; 32 positives; 1
intermediate), and mostly negative her2 status(101 negatives; 23
positives; 23 equivocals). The group also contains all 5 ofmedullary
carcinoma cases. 70 BRCA patients in C6, on the other hand, have
mixed positive and negative status for both progesterone receptor
estrogen receptor and mostly negative HER2 status (38 negatives;
8 positives; 9 others). Also, survival analysis shows higher ratio
of patients surviving longer for C4-BRCA compared to C6-BRCA.
The clinical characteristics and the survival analysis show that C4
UCEC groups patients with poor prognostic. That is, C4 UCEC in-
cludes higher ratio of serous adenocarcinoma (69/115) cases than
the common endometrioid carcinoma (45/378); the tumor grades
of the group tend to be high with 7 high-grades (out of 11 possible)
and 100 grade-3; 12 out of 30 cases are with known as ‘other malig-
nancy histological type’ within the group; and the group shows the
fastest drop of survival rates in the Kaplan-Meier plot (Fig. 3(b).)
On the other hand, UCEC patients grouped in C6 show better prog-
nostic. That is, theC6 UCEC includes large portionof endometrioid
carcinoma (312/375, precision of 0.89), large portion of tumor free
neoplasm cancer status (292/393, precision of 0.88), large portion
of low to intermediate histological grades (g1 - 87/91, g2 - 93/106),
and approximately half of grade 3 and little of grade 4 (3 out of 11).
Also, their survival ratio drop rate is less dramatic compared to C4
UCEC cases.
3.2 Prediction
3.2.1 Top-k search. When a new query patient q arrives with
data Xq which is a tensor representing the patient profile of q,
we aim to find the SNeCT factor for the patient using the pre-
calculated factor matrices and core tensor. Thus we compare the
factors of other patients which are encoded in the patient factor
matrix U(1) with the calculated patient factor. We solve the follow-
ing equation with the SNeCT algorithm while fixing parameters
other than u.
uq = argmin
u
‖Xq − G ×1 u ×2 U
(2) ×3 U
(3)‖. (6)
After generation of new profile, uq , it is used to seek top-k similar
patients by calculating the distance between the query factor and
patient factors. It takes 550ms on average to search for a query
against the training set.
3.2.2 Clinical similarity of top-k search. To test the clinical pre-
diction accuracy of SNeCT, we generated the factor matrices from
90% of the data and used 10% of the data as test set or new queries
and determined the clinical similarity of the query patient to the
Table 4: Top-k search precision.
Cohort Clinical Features Top 1 Top 5 Top 10 Top R
BRCA estrogen receptor status 0.72 0.85 0.86 0.81
progesterone receptor status 0.86 0.71 0.71 0.68
her2/neu IHC receptor status0.53 0.51 0.49 0.55
neoplasm cancer status 0.84 0.80 0.81 0.77
COAD braf gene analysis result 1.00 0.80 0.70 0.92
colon polyps present 0.47 0.56 0.52 0.59
1st relatives with cancer 0.84 0.78 0.75 0.84
venous invasion 0.61 0.60 0.63 0.72
GBM histological type 0.96 0.94 0.94 0.78
icd-o-3 histology 1.00 1.00 1.00 0.77
neoplasm cancer status 0.85 0.82 0.83 0.77
HNSC hpv status by p16 testing 0.78 0.78 0.77 0.73
KIRC histological type 1.00 0.99 0.99 0.73
icd-o-3 histology 1.00 0.99 0.99 0.73
number packs/year smoked 0.50 0.30 0.20 1.00
LAML calgb cytogenetics risk cat. 0.85 0.84 0.81 0.65
OV neoplasm histologic grade 0.79 0.75 0.76 0.77
READ braf gene analysis result 1.00 1.00 1.00 1.00
1st relatives with cancer 0.93 0.77 0.78 0.86
UCEC menopause status 0.71 0.76 0.76 0.77
neoplasm cancer status 0.83 0.75 0.77 0.77
top-k similar patients searched against factor matrixU(1). Then we
evaluated the average precision over test cases for each selected
clinical features on top-1, top-5, top-10, and top-R search results,
where the R value computes the number of samples with the same
clinical values as the query in the database and varies from query
to query. Overall, “age at initial pathologic diagnosis” and “vital
status” coincide well with all top-k retrievals with average preci-
sion over all the test data ranging from 0.76 to 0.81 and from 0.66
to 0.68, respectively. No significant features were found for LUAD,
LUSC, and BLCA other than the two clinical features. Other clini-
cal features that are cohort-specific or have high average precision
values are listed in Table 4. Looking at the precision values, we can
see that the search successfully retrieved BRCA patients with sim-
ilar estrogen and progesterone receptor status in most cases while
less so in terms of her2/neu IHC receptor status. Also, most search
results matched that of the query for the braf gene analysis results
in the COAD and READ test cases.
3.3 Personalized subtype analysis scenario
The most valuable aspects of tensor factorization results are on
the possibility of personalized interpretation of given patients. To
illustrate how factor matrices can be used for personalized inter-
pretation, we provide a brief example on a given patient i . For the
patient i , SNeCT generates patient profile u(1)i . If the patient is a
new patient we can use the Eq. 6 to generate the profile. We then
calculate the personalized subtype matrix as follows: S = G×1 u
(1)
i
(∈ RJ2×J3 ). S provides a personalized weight information for sub-
types for the gene and the platform modes. For the sample TCGA-
BS-A0UV, the center of Fig. 4 shows the heatmap of S. Each row of
S represents a subtype for gene mode, thus norm of each row rep-
resents the influence of each subtype to the patient. Each column
of S ×3 U(3) represents the platform mode. The norm of each col-
umn shows the influence of each platform to the patient and right
side of Fig. 4 shows the associated factor values. With the analysis,
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Figure 4: Personalized analysis example of patient ID TCGA-BS-A0UV in cohort UCEC assigned to cluster C12.
we can determine which gene subtypes dominantly characterize
the patient and which platform data were important in finding the
dominant characteristics such that we can trace back to the signif-
icant genes and the type of abnormality.
4 DISCUSSION AND CONCLUSIONS
In this paper, we have proposed a large-scale network constrained
Tucker decomposition method (SNeCT) that is based on paralleliz-
able stochastic gradient descent. With SNeCT, it is possible to sys-
tematically analyze high dimensional multi-platformgenomic data
constrained on prior knowledge of feature associations in a form
of a network. It is a general purpose approach that can be applied
in various combinations of multi-platform data. This is important
as the availability and variety of multi-platform genomic data in-
creases and the need for fast and intuitive methods becomes higher.
However, existing methods either run in a small-scale analysis,
combine multiple analysis methods thus requiring a large number
of hyper-parameter tuning and expert knowledge. The practicality
of SNeCT was shown on the PANCAN12 dataset where the stratifi-
cation result shows a high correlation to subsets of clinical features
and to the tissue of origin, which is consistent with the observation
made by [5]. Also, SNeCT can be applied to search for top-K simi-
lar patients given a new patient, which has various utilities such as
using the clinical features of top-k patients in diagnostics and prog-
nostic predictions. Furthermore, we showed how the combination
of factor matrices can be used for personalized genomic interpre-
tation of a patient. There are considerations to make when using
SNeCT, such as choosing normalization and gene mapping meth-
ods for construction of the input tensor, sizes of latent factors, ap-
propriate network, number of clusters in stratification studies, and
value of K in the top-K search in the clinical predictions. However,
these are common problems in analysis and several solutions can
be found in existing literature. We conclude that SNeCT provides
a powerful tool for integrative analysis of multi-platform to the
bioinformatics community.
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